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Abstract 
Purpose: To investigate the inhibitory activities of herbal compounds from Curcuma longa, Sophora 
japonica and Camellia sinensis against tumor necrosis factor alpha (TNF-α) and interleukin-1 (IL-1) 
using in vivo and in silico tools. 
Methods: The extracts of the medicinal herbs (Curcuma longa, Sophora japonica and Camellia 
sinensis) were evaluated for immune-modulatory activities based using neutrophil oxidative burst assay. 
The compounds present in the medicinal herbs were screened for their inhibitory effects against TNF-α 
(PDB ID: 2AZ5) and IL-1 (PDB ID: 2L5X) using Molegro Virtual Docker 6.0 (MVD). The stabilities of the 
top docking poses were confirmed by Molecular Dynamics (MD) simulation run for 20 nanoseconds 
(ns). 
Results: The herbal compounds exerted strong inhibitory effects against TNF-α (PDB ID: 2AZ5) and IL-
1 (PDB ID: 2L5X), implying their therapeutic potential for use in rheumatoid arthritis (RA). Of the 
compounds, curcumin diglucoside and curcumin monoglucoside showed the strongest inhibitory effects 
on monocytes, with inhibitory levels of 82.75 and 81.34 %, respectively, while eugenin had the weakest 
inhibitory activity (11.12 %). In addition, molecular docking scores were consistent with the in vivo 
results, and revealed strong inhibitory effects of curcumin diglucoside and curcumin monoglucoside 
against TNF-α and IL-1. 
Conclusion: Herbal compounds present in Curcuma longa, Sophora japonica and Camellia sinensis 
possess strong inhibitory effects against the pro-inflammatory cytokines TNF-α and IL-1. Thus, these 
compounds have therapeutic potentials that can be exploited for the treatment of RA. 
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Rheumatoid arthritis (RA) is an autoimmune 
disorder in which the immune system targets the 
joints thereby causing pain and swelling [1]. In 
some cases, the disease also affects other parts 
of the body resulting in a low red blood cell count 
and lung inflammation [2,3]. The exact cause of 
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RA is not yet fully understood, although some 
researchers reported that multiple factors such 
as obesity, smoking, genetic factors and 
environmental factors may be involved [4,5]. The 
ultimate goal of treatment of RA is to reduce the 
pain and inflammation associated with the 
disease which is usually characterized by cellular 
activation that leads to autoimmunity.  
 
The presence of immune complexes in the joints 
lead to swelling and congestion due to immune 
cell infiltration [6]. The chronic phase of the 
disease manifests in tissue injury and 
inflammation due to the release of cytokines 
such as TNF-α and IL–1 [6].These cytokines are 
produced by mononuclear leukocytes in 
response to numerous agents such as endotoxin 
and lipopolysaccharide [7,8]. Over-expression of 
TNF-α and IL-1 is a hallmark of many 
inflammatory diseases such as RA and 
inflammatory bowel disease. Thus, the two 
cytokines are potential therapeutic targets for 
these diseases. Furthermore, in several RA 
cases, the innate immune cells become activated 
and release a spectrum of pro-inflammatory 
mediators such as the TNF-α and IL-1 [9]. 
Indeed, TNF-α andIL-1 are involved in tissue 
damage and joint inflammation [10,11].  
 
In patients with RA, the concentrations of TNF-α 
and IL-1 are high in the plasma and synovial 
fluid. Thus, inhibiting the effects of these 
cytokines may be beneficial for treating a variety 
of inflammatory diseases including RA [12]. The 
current investigation was aimed at assessing the 
inhibitory effects of herbal compounds which 
possess strong medicinal properties against 
TNF-α and IL-1 using in vivo and in silico tools 




Herbal compounds  
 
Compounds present in Aloe vera, Arctiumlappa, 
Camellia sinensis, Capsicum annuum, 
Chamaemelum nobile, Curcuma longa, Curcuma 
longa, Matricari achamomilla, Matricaria recutita, 
Myrica cerifera, Senegalia catechu, Sophora 
japonica, Syzygium aromaticum, Tagetes lucida 
and Wikstroemia indica were purchased from 





Healthy human donors aged 20 - 30 years were 
used. The procedure of obtaining blood samples 
was carried out according to the guidelines of the 
ethics committee of Renmin Hospital of Wuhan 
University. Twenty milliliters of blood samples 
were collected from each subject through veno-
puncture. The samples were then transferred to 
EDTA-potassium-monovettes. 
 
Evaluation of immune-modulatory activities 
of herbal compounds 
 
The immuno-modulatory activities of the 
procured chemical compounds were evaluated 
based on chemiluminescence neutrophil 
oxidative burst assay [13]. The anti-coagulated 
blood from the healthy donors was used to purify 
the neutrophils by Percoll density gradient 
centrifugation and dextran sedimentation 
according to a slight modification of the 
procedure described by Luo et al [14]. Cells from 
the purified neutrophils were adjusted to required 
concentrations using Hank's balance salt solution 
containing Ca2+ and Mg2+ (HBSS ++). Thereafter, 
25 μL of the neutrophil cells were incubated with 
25 μL of serially-diluted 10μM solution of each 
herbal compound. After 30 min of incubation, the 
cells were washed with the serially diluted herbal 
compounds and HBSS++, and thereafter 
activated by adding 25 μL of zymosan-A, 
followed by opsonisation with further addition of 
25 μL HBSS ++. The oxidative burst results were 
monitored as chemiluminescence RLU (relative 
light unit), with peak and total integral values set 
through repeated scans at 30s intervals and one-
second point measuring time [15]. 
 
Molecular docking studies 
 
Protein retrieval  
 
Molecular docking simulation studies of the 
herbal compounds against TNF-αand IL-1were 
carried out to understand the molecular 
interactions of these compounds at the active 
sites of the enzymes and their binding 
conformations. The crystal structures of TNF-α 
(PDB ID: 2AZ5) and interleukin 1 (PDB ID: 2L5X) 
were retrieved from the Protein Data Bank. 
Structurally, 2AZ5 consists of four chains (A, B, 
C, and D) with 148 amino acids, and has a 
resolution of 2.1Å; 2L5X also consists of four 
chains with (A, B, C, and D) but with resolution of 
2.3Å. The A and D chains contain 151 amino 





The binding cavities of TNF-α (PDB ID: 2AZ5) 
and IL-1(PDB ID: 2L5X) were predicted using 
Molegro Virtual Docker 6.0 (MVD) [16]. A binding 
site of volume 2432.45Å3 and surface area 
5204.48Å2 was predicted for 2AZ5, while a 
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binding site volume of 33.28 Å3 and a surface 
area of 143.36Å2was predicted for 2L5X. The 
binding site was set inside a restricted sphere of 
X: -15.92, Y: 67.52, and Z: 26.91 for 2AZ5. For 
2L5X, the corresponding values were X: 36.43, 
Y: 2.84, and Z: 12.99. The two binding sites had 
a radius 17Å and a grid resolution of 0.30Å. 
 
Chemical data set 
 
The 2D structures of the herbal compounds were 
retrieved from the NCBI PubChem database [17] 
and their structures were optimized and 





For the molecular docking simulation, only the A 
chains of both enzymes were considered. The 
herbal compounds and the protein structures 
were imported in MVD. The bond flexibility for the 
side chains of the amino acids was set for the 
assigned sphere within the restriction of 17 Å of 
the binding cavity. The flexibility was set with a 
value of 1.10 tolerance and 0.90 strengths. The 
RMSD threshold for the multiple cluster poses 
was set at 2.00 Å with energy penalty value of 
100.00. The docking algorithm was with a 
maximum iteration of 1500 and a simplex 
evolution size of 50. The docking simulation was 
run at least 100 times for 10 poses and the best 
poses were chosen based on the Rerank score, 
MolDock score and interaction energy [18]. 
 
Molecular dynamics (MD) simulation 
 
The MD simulations for the protein-ligand docked 
complexes were carried out using GROMACS 
5.0 installed in Ubuntu Linux 15.0 LTS powered 
with Intel i7 processor, 8GB RAM [19]. The 
simulations were processed with standard 
GROMOS96 43a1 force field (25). The MD 
simulation was carried out for the top docking hit 
protein-ligand complexes of TNF-α (PDB ID: 
2AZ5) and IL-1 (PDB ID: 2L5X). Initially, the 
system was immersed in a cubic water box and 
the energy of the complexes was minimized 
using the approach of steepest descent energy 
minimization [20]. Furthermore, the systems 
were equilibrated for 100ps with NVT-canonical 
(number of particles, volume, and temperature) 
and NPT-isothermal–isobaric (number of 
particles, pressure, and temperature) after 
energy minimization and ensemble with the 
equilibration protocol for another 5000 steps. The 
equilibrated system was programmed for 20-
nanosecond (ns) production of MD simulation. 
During the MD production, the system was held 
under a constant number of particles at 310K 
and a pressure of 1 bar. The generated trajectory 
during the 20 ns run was analyzed based on the 
RMSD backbone of the docked-ligand 




The evaluation of the immune-modulatory 
activities of the herbal compounds and their 
medicinal potential for the treatment of RA 
revealed that these compounds possessed 
strong inhibitory effects on monocytes. Curcumin 
diglucoside and curcumin monoglucoside had 
the strongest inhibitory effects, with inhibitory 
levels of 82.75 and 81.34 %, respectively. On the 
other hand, eugenin produced the weakest 
immuno-modulatory and inhibitory effect of 11.12 
%. These results are are detailed in Table 1.  
 
The molecular docking scores of the herbal 
compounds against TNF-α (PDB ID: 2AZ5) and 
IL-1 (PDB ID: 2L5X) are presented in Table 2, 
which depicts the scores and results based on 
ascending order of the re-rank score, and the 
MolDock scores and interaction energies. 
Curcuma longa, Camellia sinensis and Sophora 
japonica had strong molecular interactions at the 
potential ligand binding sites of TNF-α (PDB ID: 
2AZ5) and IL-1 (PDB ID: 2L5X). The ligand-
protein interaction analyses of the top docked 
herbal compounds with TNF-α (PDB ID: 2AZ5) 
and IL-1 (PDB ID: 2L5X) are presented in Table 
3 and Table 4, respectively. The ligand-protein 
interaction analysis was carried out to 
understand the in-depth molecular interaction of 
these docked herbal compounds at the active 
site of TNF-α(2AZ5) and IL-1 (2L5X), and its 
binding mechanism. Curcumin diglucoside, 
curcumin monoglucoside and sophoricoside 
docked at the binding cavity of TNF-α (2AZ5) 
with rerank scores of -84.50 kJ-mol-1, -83.45 kJ-
mol-1 and -75.55 kJ-mol-1, respectively. The 
binding modes of the docked compounds with 
TNF-α (PDB ID: 2AZ5) and IL-1 (PDB ID: 2L5X) 
are illustrated in Figures 1-6. The trajectory 
profiles which depict the RMSD backbones of the 
2AZ5ligand-docked complexes and 2L5Xligand-
docked complexes from production of MD 





The pro-inflammatory cytokines TNF-αandIL-1 
are major catabolic factors in cartilage 
metabolism. There are several reports on the 
targeting of these enzymes for potential 
therapeutic applications [21]. 
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Table 1: Immuno-modulating and inhibitory properties of the herbal compounds studied 
 
Compound Plant source RLU* Inhibition (%) 
Curcumin Diglucoside Curcuma longa 104.2 ± 0.2 82.8 
Curcumin Monoglucoside Curcuma longa 107.7 ±  0.1 81.3 
Epigallocatechin gallate Camellia sinensis 124.1 ± 0.4 79.9 
Sophoricoside  Sophora japonica 129.2 ± 0.7 79.7 
Arctiin Arctium lappa 156.7 ± 1.0 75.5 
Capsaicin  Capsicum annuum 166.7 ± 1.2 74.2 
Daphnoretin Wikstroemia indica 309.5 ± 1.1 63.1 
Isorhamnetin Tagetes lucida 330.5 ± 2.1 61.3 
Catechin Senegalia catechu 380.9 ± 2.3 53.2 
Myricetin Myrica cerifera 390.6 ± 2.7 50.3 
Bisabolol Matricaria recutita 401.4 ± 3.9 48.1 
Kaempferol Aloe vera 580.1 ± 3.2 21.5 
Chamazulene Matricaria chamomilla 680.1 ± 5.2 19.1 
Apigenin Chamaemelum nobile 731.1 ± 7.6 15.2 
Eugenin Syzygium aromaticum 877.3 ± 9.7 11.1 
*Values are mean ± SD 
 




TNF-α (2AZ5)  
Compound 
 














Diglucoside -91.24 -84.50 -8.42 
Curcumin 
Diglucoside -138.50 -115.43 -9.34 
Curcumin 
Monoglucoside -99.61 -83.45 -2.70 
curcumin 
monoglucoside -124.33 -101.02 -8.15 
Sophoricoside  -82.78 -75.55 -9.49 
Epigallocate-chin 
gallate -120.75 -96.58 -11.65 
Arctiin -96.59 -71.98 -8.78 Sophoricoside  -94.70 -80.09 -13.48 
Capsaicin  -86.48 -66.85 -1.80 Arctiin -135.02 -79.70 -4.00 
Epigallocat-
echingallate -90.90 -65.98 -14.72 Capsaicin  -104.21 -75.82 -2.24 
Daphnoretin -75.14 -59.53 -4.79 Daphnoretin -87.19 -70.87 -3.14 
Isorhamnetin -66.50 -59.45 -5.78 Bisabolol -84.00 -65.64 -1.40 
CID 9064 -70.51 -59.18 -8.73 CID 9064 -76.16 -63.67 -12.94 
Myricetin -62.50 -59.03 -7.34 Isorhamnetin -71.16 -59.85 -5.19 
Bisabolol -71.25 -58.00 -3.90 Ibuprofen -68.61 -57.93 -2.24 
Kaempferol -64.93 -56.15 -7.98 Myricetin -64.84 -55.04 -9.09 
Chamazulene -65.06 -54.22 0.00 Chamazulene -64.85 -54.61 0.00 
Apigenin -62.25 -52.21 -5.55 Kaempferol -61.00 -54.40 -4.02 
Ibuprofen -58.55 -50.77 -6.12 Apigenin -68.16 -53.97 -4.30 
Eugenin -55.12 -42.42 -2.86 Eugenin -53.75 -46.95 -2.50 
 
Table 3: Molecular interaction analysis of the top hits with TNF-α (2AZ5) 
 
Compound Interacting amino acid  Interaction energy 
 (kJ-mol-1) 
Interaction distance 
Curcumin diglucoside Asn39(ND) -2.50 3.08 Å 
Lys11(N) -0.66 3.23 Å 
Lys11(O) -2.50 2.78 Å 
Ala156(O) -2.50 2.67 Å 
Gly121(N) -0.32 3.02 Å 
Gly121(O) -2.5 2.66 Å 
Curcumin monoglucoside His15(O) -2.0 3.20 Å 
Leu36(N) -2.2 2.56 Å 
Gly121(O) -2.5 2.74 Å 
Sophoricoside Tyr59(OH) -0.47 2.36 Å 
Tyr151(OH) -1.71 3.26 Å 
Tyr151(OH) -2.5 3.06 Å 
Gln61(OE) -2.36 3.13 Å 
Ser60(O) -2.5 2.61 Å 
Leu120(N) -1.36 2.87 Å 
Leu120(O) -2.5 2.70 Å 
Leu120(O) -2.15 3.17 Å 
ND: Nitrogen δ atom; N: Nitrogen; O: Oxygen; OE: Oxygen ε atom; OH: Hydroxyl group 
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Table 4: Molecular interaction analysis of the top hits with IL-1 (2L5X) 
 




Curcumin diglucoside Asp49(OD) -0.15 3.56  
Ser75(O) -1.25 3.35  
Glu21(OE) -2.5 2.68  
His46(NE) -2.29 3.09  
Glu50(OE) -2.37 3.12  
Glu50(OE) -2.50 3.00  
Asn47(OD) -1.40 3.05  
Arg34(O) -0.28 3.54  
Curcumin monoglucoside Asp49(OD) -2.11 3.18 
Asp49(O) -2.50 2.66 
Asn47(OD) -1.50 3.29 
Asn47(OD) -2.50 2.82 
Glu50(O) -2.50 2.62 
Arg34(O) -2.50 2.79 
Epigallocatechin gallate Glu50(OE) -0.14 3.57 
Glu50(O) -1.63 3.27 
Asp49(O) -1.69 3.26  
Asp49(OD) -2.46 3.11  
Asp49(OD) -0.13 3.42  
Arg34(O) -2.27 2.57  
Asn47(OD) -2.50 2.64  
Thr77(OG) -1.95 3.21  







Figure 1: (A) Binding mode of curcumin diglucoside 
(green color) at the active site of TNF-α (PDB ID: 
2AZ5); (B) Secondary structure depicting the 
molecular interactions between curcumin diglucoside 







Figure 2: (A) Binding mode of curcumin 
monoglucoside (green color) at the active site of TNF-
α (PDB ID: 2AZ5). (B) Secondary structure depicting 
the molecular interactions between curcumin 
monoglucoside and His15, Leu36 and Gly121 
residues 
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Figure 3: (A) Binding mode of sophoricoside (green 
color) at the active site of TNF-α (PDB ID: 2AZ5). (B) 
Secondary structure depicting the molecular 
interactions between sophoricoside and Tyr59, Ser60, 







Figure 4: (A) Binding mode of curcumin diglucoside 
(yellow color) at the active site of ofIL-1 (PDB ID: 
2L5X). (B) Secondary structure depicting the 
molecular interactions between curcumin diglucoside 








Figure 5: (A) Binding mode of curcumin 
monoglucoside (yellow color) at the active site of IL-1 
(PDB ID: 2L5X).(B) Secondary structure depicting the 
molecular interactions between curcumin 
monoglucoside and Arg34, Asn47, Asp49 and Glu50 
residues 
 
In this study, drug targets for these proteins were 
identified and virtual screening was carried out. 
Molecular docking analysis of binding is an 
essential step in the drug discovery process. It 
gives a picture of the binding mode of a 
compound under investigation. The results of the 
present study show that the herbal compounds 
present in Curcuma longa produced the 
strongest inhibitory effects on monocytes. 
Curcumin diglucoside and curcumin 
monoglucoside which are constituents of 
Curcuma longa elicited strong immune-
modulatory and monocyte-inhibitory effects 
based on the neutrophil oxidative burst assay. 
The strong inhibitory effects on monocytes are 
bound to have significant impact on the 
production of inflammatory cytokines, TNF-α and 
IL-1. 
 
Epigallocatechin gallate, sophoroside and arctin 
also showed good immune-modulating and 
inhibitory effects. This study also demonstrated 
the effectiveness of combining molecular docking 
studies with functional assays for the discovery 
Xu et al 
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and development of novel small-molecule drugs 







Figure 6: (A) Binding mode of epigallocatechin gallate 
(yellow color) at the active site of IL-1 (PDB ID: 
2L5X).(B) Secondary structure depicting the molecular 
interactions between epigallocatechin gallate and 
Arg34, Asn47, Asp49 and Glu50 residues 
 
 
Figure 7: RMSD backbone of 2AZ5ligand-docked 
complexes during the 20ns MD simulation run 
 
The results from molecular docking analyses of 
the herbal compounds against TNF-α (PDB ID: 
2AZ5) and IL-1 (PDB ID: 2L5X) correlate with 
results from assays of immuno-modulatory 
activities. The herbal compounds present in 
Curcuma longa, Camellia sinensis and Sophora 
japonica had strong molecular interactions at the 
potential ligand binding sites of TNF-α (PDB ID: 
2AZ5) and IL-1 (PDB ID: 2L5X). The key 
interactions (bonded and non-bonded) were 
formed between the docked compounds and the 
binding cavities of these enzymes. 
 
 
Figure 8: RMSD backbone of 2L5Xligand-docked 
complexes during the 20ns MD simulation run.  
 
Molecular docking simulation analysis revealed 
that curcumin diglucoside, curcumin 
monoglucoside and sophoricoside docked at the 
binding cavity of TNF-α (2AZ5) with rerank 
scores of -84.50 kJ-mol-1, -83.45 kJ-mol-1 and -
75.55 kJ-mol-1, respectively. Interestingly, 
curcumin diglucoside and curcumin 
monoglucoside also docked at the binding cavity 
of IL-1 (2L5X) with rerank scores of -115.43 kJ-
mol-1 and -101.02 kJ-mol-1, respectively. These 
results are consistent with data from the assay of 
immuno-modulatory activities. On the other hand, 
eugenin showed the weakest docking score with 
a rerank score of  -42.42 kJ-mol-1forTNF-α 
(2AZ5), and -46.95 kJ-mol-1for IL-1(2L5X). The 
rerank scoring function is actually more 
expensive in computational terms than the 
scoring function used during the docking 
simulation but it is generally better than the 
docking score function. 
 
Results from the introduction of ibuprofen during 
the docking simulation validated the docking 
protocol used. Ibuprofen is a known inhibitor of 
TNF-α (2AZ5) and IL-1 (2L5X). The investigated 
herbal compounds produced more favorable 
docking scores (Rerank and MolDock) for 2AZ5 
and 2L5X than ibuprofen. The molecular docking 
simulation also revealed that the top docking 
poses were docked into binding cavities 
exhibiting both bonded as well as non-bonded 
interactions. The ligand–protein interaction 
analyses using ligand energy inspector revealed 
the interaction distances and interaction energies 
of the docked compounds with the corresponding 
amino acid residues. In case of TNF-α (2AZ5), 
curcumin diglucoside interacted with Lys11, 
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Asn39, Gly121, and Ala156; curcumin 
monoglucoside with His15, Leu36 and Gly121 
and sophoricoside with Tyr59, Ser60, Gln61, 
Leu120, and Tyr151.  
 
Earlier, Takasaki et al proposed a similar 
molecular docking approach used for successful 
identification of a small molecule which inhibited 
TNF-α at the same binding site that formed 
hydrogen bonds with Asn39, Tyr59, Gln61 and 
Gly121 [22].Similar results have also been 
obtained by Ma et al [23], which are in 
agreement with the results obtained in the 
present study. 
 
With respect to IL-1 (2L5X), curcumin diglucoside 
showed interactions with Glu21, Arg34, His46, 
Asn47, Asp49, Glu50 and Ser75; curcumin 
monoglucoside interacted with Arg34, Asn47, 
Asp49 and Glu50 while epigallocatechin gallate 
showed interaction with Arg34, Asn47, Asp49, 
Glu50 and Thr77.  
 
The molecular interactions with Arg34, Asn47, 
Asp49, and Glu50 of IL-1 are also in agreement 
with data reported by Wu et al which specifically 
implicated these amino acid residues in the 
binding mode of resveratrol docked against IL-1 
[15]. Moreover, the molecular interaction 
distance of the docked herbal compounds 
confirmed strong binding affinities as were 
evident from energy scores. The interaction 
energies also revealed that majority of the 
interactions were within 3.5Å, close enough to 
elicit strong inter- molecular forces. 
 
Since the biological activity of any drug is based 
on the binding between a receptor (protein) and 
a ligand (drug), the results of the present 
investigation indicate that the investigated herbal 
compounds have strong binding affinities for the 
pro-inflammatory cytokines studied. This is 
strong evidence of their inhibitory potential. 
Furthermore, the backbone root mean square 
deviation (RMSD) values of protein and protein-
ligand complex during 20ns of MD simulations for 
TNF-α(2AZ5) ligand-docked complex and IL-1 
(2L5X) ligand-docked complex indicate the 
stability of the protein-ligand complexes. This is 
confirmation of conformational flexibility and 
stability in dynamic behavior. In both cases, the 
apo enzymes (2AZ5 and 2L5X) and the docked 
ligand complexes showed stability right from the 
launch of the MD run with stable conformations 
throughout the simulation period,  except for 
2L5X-epigallocatechin gallate-docked complex 
which drifted at 7ns and 13ns, probably as a 
result of the chemical nature of the compound. 
CONCLUSION 
 
The herbal compounds present in Curcuma 
longa, Sophora japonica, and Camellia sinensis 
possess strong inhibitory potentials against TNF-
α and IL–1. The immune-modulatory activities of 
the herbal compounds also reveal the 
therapeutic potential of these herbal compounds 
for use in RA. In addition, molecular docking 
simulation results show that curcumin 
diglucoside, curcumin monoglucoside, 
sophoricoside and epigallocatechin gallate inhibit 
TNF-α and IL–1 with strong molecular 
interactions as evidenced by their molecular 
docking scores and ligand-protein interaction 
energies. Thus, curcumin diglucoside, curcumin 
monoglucoside, sophoricoside and 
epigallocatechin gallate are bioactive compounds 
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